-
Uncategorized2 months agoSTAT+: GSK advancing ovarian cancer drug mo-rez
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. It’s been a minute since...
-
Uncategorized2 months ago
Light makes plants stronger but also holds them back
Light doesn’t just help plants grow—it may also quietly hold them back. Researchers have uncovered a surprising mechanism where light strengthens the “glue” between a plant’s...
-
Uncategorized2 months ago
Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3
Revolution Medicines reported Monday that its experimental KRAS inhibitor called daraxonrasib succeeded in a registrational trial for pancreatic cancer. And now, the company plans to ask...
-
Uncategorized2 months agoSTAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in...
-
Uncategorized2 months ago
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
-
Uncategorized2 months agoSTAT+: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients
Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving...
-
Uncategorized2 months ago
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US....
-
Uncategorized2 months ago
Rethinking dermatology trial design for late-stage success
A smarter approach to dermatology trials—built for durability and real-world impact. Read More
-
Uncategorized2 months agoSTAT+: Hospitals roll out chatbots, looking to reclaim their role in patients’ health conversations
Every day, more than 40 million people ask ChatGPT about health care, according to OpenAI. They’re asking questions about diet, exercise, insurance — and in some...
-
Uncategorized2 months ago
Seaport and Hemab file for IPOs, with Kailera expected to price soon
The spring IPO cohort is starting to take shape. On Friday night, neuroscience drug developer Seaport Therapeutics and blood clotting disorder biotech Hemab Therapeutics both filed...
